• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Boston Scientific Corporation

    5/8/26 4:15:47 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email
    S-8 1 tm2613764d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 8, 2026

     

    Registration No. 333-              

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Boston Scientific Corporation
    (Exact name of registrant as specified in its charter)
       
       
    Delaware 04-2695240
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer Identification No.)
       

    300 Boston Scientific Way

    Marlborough, Massachusetts

    01752
    (Address of Principal Executive Offices) (Zip Code)
       
       
    BOSTON SCIENTIFIC CORPORATION EMPLOYEE STOCK PURCHASE PLAN
    (Full title of the plan)

     

    Vance R Brown
    Executive Vice President, General Counsel and
    Corporate Secretary
    Boston Scientific Corporation
    300 Boston Scientific Way
    Marlborough, Massachusetts 01752
    (508) 683-4000

    (Name, address, telephone number,
    including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company  ¨ Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) relates to the registration of 10,000,000 shares (the “Shares”) of the common stock, par value $0.01 per share, of Boston Scientific Corporation (the “Registrant”). The Shares are securities of the same class and relate to the same employee benefit plan, the Boston Scientific Corporation Employee Stock Purchase Plan, as those registered pursuant to the Registrant’s registration statement on Form S-8 (File Number 333-264754), previously filed with the Securities and Exchange Commission (the “Commission”) on May 6, 2022, on Form S-8 (File Number 333-196672), previously filed with the Commission on June 11, 2014, on Form S-8 (File Number 333-174620), previously filed with the Commission on May 31, 2011 and on Form S-8 (File Number 333-134932), previously filed with the Commission on June 9, 2006 (the “Prior Registration Statements”). In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the new information set forth below.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by the Registrant with the Commission are incorporated herein by reference and shall be deemed to be a part hereof:

     

    (1)        The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on February 17, 2026;

     

    (2)         The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Commission on May 1, 2026;

     

    (3)        The Registrant’s Current Reports on Form 8-K filed with the Commission on the following dates in 2026: January 15, 2026 (SEC Accession No. 0000947871-26-000037), February 5, 2026, February 23, 2026, February 26, 2026, March 30, 2026 and May 5, 2026 (provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to Form 8-K shall not be incorporated by reference into this Registration Statement); and

     

    (4)        The description of the Registrant’s Common Stock under the heading “Description of Common Stock” contained in the Registration Statement on Form S-3 (Registration No. 333-132626) as originally filed by the Registrant with the Commission on March 22, 2006, including any reports filed that updated such description.

     

    In addition, all documents that the Registrant files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.

     

    For purposes of this Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    EXHIBIT

    NUMBER

      DESCRIPTION
         
    4.1   Fourth Restated Certificate of Incorporation of Boston Scientific Corporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 5, 2026).
         
    4.2   Amended and Restated By-laws of Boston Scientific Corporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 10, 2024).
         
    4.3   Specimen Certificate for shares of the Company's Common Stock (incorporated herein by reference to Exhibit 4.1, Form S-1 Registration No. 33-46980).
         
    4.4   Boston Scientific Corporation Employee Stock Purchase Plan, Amended and Restated effective as of July 1, 2026 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 5, 2026).
         
    5.1   Opinion of Baker & McKenzie LLP.
         
    23.1   Consent of Ernst & Young LLP, independent Registered Public Accounting Firm.
         
    23.2   Consent of Baker & McKenzie LLP (contained in Exhibit 5.1).
         
    24.1   Power of Attorney (included on signature page of this Registration Statement).
         
    107   Filing Fee Table

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Marlborough, Commonwealth of Massachusetts, on May 8, 2026.

     

      BOSTON SCIENTIFIC CORPORATION
       
      By: /s/ Jonathan R. Monson
      Name: Jonathan R. Monson
      Title: Executive Vice President and Chief Financial Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael F. Mahoney, Jonathan R. Monson, Vance R. Brown, and Susan J. Thompson, each acting alone, his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments including post-effective amendments to this Registration Statement on Form S-8 (including, without limitation, any additional registration statement filed pursuant to Rule 462 under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his or her substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name Position Date
         
      Executive Vice President and Chief  
    /s/ Jonathan R. Monson Financial Officer May 8, 2026
    Jonathan R. Monson (Principal Financial Officer)  
         
      Director, Chairman of the Board,  
    /s/ Michael F. Mahoney President and Chief Executive Officer May 8, 2026
    Michael F. Mahoney (Principal Executive Officer)  
         
      Senior Vice President, Global Controller and  
    /s/ Emily Woodworth Chief Accounting Officer May 8, 2026
    Emily Woodworth (Principal Accounting Officer)  
         
         
    /s/ David C. Habiger Director May 8, 2026
    David C. Habiger    
         
    /s/ Edward J. Ludwig Director May 8, 2026
    Edward J. Ludwig    
         
    /s/ Jessica L. Mega Director May 8, 2026
    Jessica L. Mega    
         
    /s/ Susan E. Morano Director May 8, 2026
    Susan E. Morano    
         
    /s/ Cheryl Pegus Director May 8, 2026
    Cheryl Pegus    
         
    /s/ Cathy R. Smith Director May 8, 2026
    Cathy R. Smith    
         
    /s/ Christophe P. Weber Director May 8, 2026
    Christophe P. Weber    
         
    /s/ David S. Wichmann Director May 8, 2026
    David S. Wichmann    
         
    /s/ Ellen M. Zane Director May 8, 2026
    Ellen M. Zane    

     

     

     

     

    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX

    DatePrice TargetRatingAnalyst
    5/29/2026Outperform → Peer Perform
    Wolfe Research
    5/28/2026$55.00Overweight → Equal Weight
    Wells Fargo
    3/30/2026$88.00Strong Buy → Outperform
    Raymond James
    10/3/2025Buy → Hold
    Erste Group
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    6/16/2025$118.00Outperform
    Leerink Partners
    4/16/2025$113.00Hold → Buy
    Needham
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $BSX
    SEC Filings

    View All

    SEC Form SD filed by Boston Scientific Corporation

    SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/21/26 4:16:28 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/18/26 7:17:15 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/18/26 7:15:03 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boston Scientific downgraded by Wolfe Research

    Wolfe Research downgraded Boston Scientific from Outperform to Peer Perform

    5/29/26 8:06:22 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Boston Scientific from Overweight to Equal Weight and set a new price target of $55.00

    5/28/26 8:45:02 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Raymond James with a new price target

    Raymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00

    3/30/26 8:15:23 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:10 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:20:09 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    6/1/26 4:18:00 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:10 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

    Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well a

    5/19/26 6:31:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific enters into $2 billion accelerated share repurchase agreement

    MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, Boston Scientific will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52

    5/18/26 7:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces strategic investment in MiRus LLC

    Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloyMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has invested $1.5 billion in return for an approximately 34% equity stake in MiRus LLC, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. As part of the investment agreement, Boston Scientific also received an exclusive option to acqu

    5/18/26 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Financials

    Live finance-specific insights

    View All

    Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

    MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Mike Mahoney, chairman and chief executive officer, and Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. Additionally, the company will webcast its conference call discussing financial results and business highlights for the second quarter end

    5/4/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces results for first quarter 2026

    MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion or $0.90 per share (EPS), compared to $674 million or $0.45 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.75 a year ago. "Our global

    4/22/26 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces conference call discussing first quarter 2026 results

    MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev

    3/30/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Leadership Updates

    Live Leadership Updates

    View All

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    4/3/25 11:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 11:49:03 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 8:35:54 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care